INO-8875: Clinical Trials

4 trials of INO-8875, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 2 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 2
Phase 31Completed 1

Follow INO-8875: new trials by email Literature Review of INO-8875 trials Research Report on INO-8875

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 3CompletedInotek Pharmaceuticals Corporation3032015-09-012016-12-06
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 2CompletedInotek Pharmaceuticals Corporation1012013-08-012017-12-02
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
INO-8875, Placebo - Glaucoma, Ocular Hypertension
Phase 1 / Phase 2CompletedInotek Pharmaceuticals Corporation1442010-05-012012-10-15
Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers
INO-8875, Placebo control - Health
Phase 1CompletedInotek Pharmaceuticals Corporation702010-05-012012-04-30

Conditions studied

Glaucoma (3)  ·  Glaucoma, Open-Angle (3)  ·  Ocular Hypertension (3)

Sponsors

Inotek Pharmaceuticals Corporation (4)

Countries

United States (4)

Top investigators

Cadmus C Rich, MD,MBA,CPE (1)